2. PRINCIPLES
• Lysosomal storage disease
• Ethnic variation in allele frequencies
• Genetic drift
• Pseudo-deficiency
• Population screening
3. MAJOR PHENOTYPIC FEATURES
• Age at onset: infancy through adulthood
• Neurodegeneration
• Retinal cherry-red spot
• Psychosis
4. Disease Etiology and Incidence
Tay-Sachs disease autosomal recessive disorder of ganglioside
(oligosaccharides) catabolism that is caused by deficiency of
hexosaminidase A.
The enzyme deficiency varies widely among different populations; the
incidence of Tay-Sachs disease ranges from 1 in 3600 Ashkenazi Jewish
birth to 1 in 360,000 non–Ashkenazi Jewish North American births.
5. Pathogenesis
Hexosaminidase A is a lysosomal enzyme composed of two subunits.
The α subunit is encoded by the HEXA gene on chromosome 15, and
the β subunit is encoded by the HEXB gene on chromosome 5.
HEXA codes for the α subunit of the enzyme β hexosaminidase A.
Mutations of the α subunit or the activator protein cause the
accumulation of GM2 in the lysosome and thereby Tay-Sachs disease
6. β Hexosaminidase A
Normally β hexosaminidase A helps to degrade a lipid called GM2
ganglioside, but in the case, the enzyme is absent allowing excessive
accumulation of GM2 ganglioside in the lysosomes of the neurons.
The large built up of gangliosides in the neurons of the brain results in
marked degenerative changes in the CNS & death occurs before 4 years
of age.
11. TYPES OF TAY-SACH DISEASE
(Phenotype)
Based on the onset age of neurological symptoms, the disease is classified
into several forms
Infantile acute form:
-Most common and fatal (by age of 5)
Juvenile onset:
-Anywhere from 6-16 yrs - crippling
Adult/late onset:
-30 to 40 yrs - life shortening - slower progressing
12. Infantile Tay-Sachs Disease
Infants with Tay–Sachs disease characterized by neurological
deterioration between 3 to 6 months of age and progressing to death by
2 to 4 years.
Visual loss associated with CHERRY-RED SPOT is characterized.
13. Juvenile Tay–Sachs Disease
Initially seen in children between two and ten years old.
Patient develop cognitive and motor
skill deterioration, dysarthria, dysphagia, ataxia, and spasticity.
Death usually occurs between the age of five to fifteen years.
14. Adult/Late-Onset Tay–Sachs Disease
Symptoms seen in adolescence or early adulthood – include speech and
swallowing difficulties, unsteadiness of gait, spasticity, cognitive decline,
and psychiatric illness, particularly a schizophrenia-like psychosis.
16. DIAGNOSIS
Eye examination (reveals a cherry-red spot in the macula).
Enzyme analysis of blood or body tissue for hexosaminidase levels (2
pseudo-deficiency alleles and more than 70
pathological mutations have
been identified in the HEX A gene).
19. MANAGEMENT
Tay-sach disease is currently an incurable disorder, therefore treatment
focuses on the management of symptoms and palliative care.
Nearly all patients require pharmacological management of their
seizures.
The psychiatric manifestations of patients with adult-onset are not
usually responsive to antidepressant medication.
20. References
GeneTests. Medical genetics information resource [database online]. University of Washington, Seattle,
1993-2006. Updated weekly. http://www.genetests.org
OMIM: Online Mendelian Inheritance in Man. McKusick-Nathans Institute for Genetic Medicine, Johns
Hopkins University, and National Center for Biotechnology Information, National Library of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
Ross LF: Heterozygote carrier testing in high schools abroad: what are the lessons for the U.S.? J Law
Med Ethics 34:753-764, 2006.
IMAGES:
http://images.slideplayer.com/18/6171172/slides/slide_6.jpg
http://www.healthandfitnesstalk.com/wp-content/uploads/2013/08/taysachs.gif
http://myscienceacademy.org/wp-
content/uploads/2012/09/564857_522835031063904_1634463179_n.jpg
https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSuK_zd7Zn7XZwBVGqIYHxl_gz6rn-
yoqV3TjP-wauKuDBcM1mA